Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KURA |
---|---|---|
09:32 ET | 144479 | 10.065 |
09:33 ET | 404590 | 10.05 |
09:35 ET | 138658 | 10 |
09:37 ET | 65057 | 10.0747 |
09:39 ET | 36736 | 10.325 |
09:42 ET | 57502 | 10.5662 |
09:44 ET | 34812 | 10.58 |
09:46 ET | 118577 | 10.76 |
09:48 ET | 101640 | 10.7 |
09:50 ET | 35609 | 10.8101 |
09:51 ET | 55254 | 10.82 |
09:53 ET | 77661 | 10.9698 |
09:55 ET | 44250 | 10.85 |
09:57 ET | 6832 | 10.865 |
10:00 ET | 36077 | 10.85 |
10:02 ET | 169842 | 10.88 |
10:04 ET | 11196 | 10.82 |
10:06 ET | 8465 | 10.75 |
10:08 ET | 80045 | 10.935 |
10:09 ET | 50542 | 10.99 |
10:11 ET | 39526 | 10.9498 |
10:13 ET | 8333 | 10.975 |
10:15 ET | 87817 | 10.84 |
10:18 ET | 8249 | 10.91 |
10:20 ET | 22469 | 10.94 |
10:22 ET | 14066 | 10.935 |
10:24 ET | 28949 | 10.95 |
10:26 ET | 93768 | 11 |
10:27 ET | 293514 | 10.98 |
10:29 ET | 15414 | 10.98 |
10:31 ET | 32815 | 10.98 |
10:33 ET | 6586 | 10.975 |
10:36 ET | 12508 | 10.98 |
10:38 ET | 6548 | 11 |
10:40 ET | 10581 | 10.985 |
10:42 ET | 7708 | 11.005 |
10:44 ET | 5638 | 10.985 |
10:45 ET | 19191 | 10.995 |
10:47 ET | 5801 | 10.985 |
10:49 ET | 445056 | 11 |
10:51 ET | 42393 | 11 |
10:54 ET | 11285 | 10.9929 |
10:56 ET | 23658 | 11 |
10:58 ET | 281819 | 11.0028 |
11:00 ET | 15262 | 10.995 |
11:02 ET | 6707 | 10.985 |
11:03 ET | 6802 | 10.975 |
11:05 ET | 24032 | 10.99 |
11:07 ET | 22192 | 11 |
11:09 ET | 20600 | 11 |
11:12 ET | 15450 | 10.99 |
11:14 ET | 37837 | 10.985 |
11:16 ET | 47284 | 11 |
11:18 ET | 42398 | 10.99 |
11:20 ET | 10087 | 10.99 |
11:21 ET | 15335 | 10.99 |
11:23 ET | 27802 | 11 |
11:25 ET | 15889 | 11.005 |
11:27 ET | 14023 | 10.995 |
11:30 ET | 24249 | 11 |
11:32 ET | 21953 | 11 |
11:34 ET | 28429 | 10.98 |
11:36 ET | 23622 | 11 |
11:38 ET | 17170 | 10.98 |
11:39 ET | 5025 | 11 |
11:41 ET | 4650 | 11 |
11:43 ET | 7432 | 11 |
11:45 ET | 7779 | 10.98 |
11:48 ET | 21708 | 10.97 |
11:50 ET | 27953 | 10.92 |
11:52 ET | 26993 | 10.94 |
11:54 ET | 8888 | 10.98 |
11:56 ET | 7460 | 10.95 |
11:57 ET | 2665 | 10.88 |
11:59 ET | 8125 | 10.9382 |
12:01 ET | 6442 | 10.9316 |
12:03 ET | 4200 | 10.92 |
12:06 ET | 7143 | 10.95 |
12:08 ET | 7368 | 10.92 |
12:10 ET | 4100 | 10.88 |
12:12 ET | 8746 | 10.85 |
12:14 ET | 7376 | 10.77 |
12:15 ET | 1894 | 10.82 |
12:17 ET | 2300 | 10.82 |
12:19 ET | 8154 | 10.85 |
12:21 ET | 2087 | 10.85 |
12:24 ET | 4352 | 10.82 |
12:26 ET | 27017 | 10.85 |
12:28 ET | 10262 | 10.84 |
12:30 ET | 23940 | 10.85 |
12:32 ET | 5412 | 10.86 |
12:33 ET | 6867 | 10.885 |
12:35 ET | 5994 | 10.8599 |
12:37 ET | 2084 | 10.8554 |
12:39 ET | 1580 | 10.87 |
12:42 ET | 1757 | 10.88 |
12:44 ET | 6191 | 10.86 |
12:46 ET | 2146 | 10.86 |
12:48 ET | 7912 | 10.91 |
12:50 ET | 4868 | 10.89 |
12:51 ET | 12360 | 10.88 |
12:53 ET | 5129 | 10.9 |
12:55 ET | 6553 | 10.865 |
12:57 ET | 8592 | 10.88 |
01:00 ET | 8679 | 10.855 |
01:02 ET | 13893 | 10.85 |
01:04 ET | 1900 | 10.855 |
01:06 ET | 5015 | 10.85 |
01:08 ET | 5688 | 10.835 |
01:09 ET | 3670 | 10.87 |
01:11 ET | 24549 | 10.795 |
01:13 ET | 6289 | 10.84 |
01:15 ET | 805 | 10.86 |
01:18 ET | 2574 | 10.88 |
01:20 ET | 6591 | 10.89 |
01:22 ET | 3062 | 10.91 |
01:24 ET | 4157 | 10.92 |
01:26 ET | 17146 | 10.855 |
01:27 ET | 2167 | 10.85 |
01:29 ET | 2393 | 10.86 |
01:31 ET | 8817 | 10.86 |
01:33 ET | 2950 | 10.87 |
01:36 ET | 6625 | 10.84 |
01:38 ET | 13178 | 10.86 |
01:40 ET | 2522 | 10.865 |
01:42 ET | 2320 | 10.85 |
01:44 ET | 12339 | 10.8101 |
01:45 ET | 1226 | 10.83 |
01:47 ET | 2072 | 10.85 |
01:49 ET | 16423 | 10.87 |
01:51 ET | 6008 | 10.85 |
01:54 ET | 9763 | 10.815 |
01:56 ET | 1466 | 10.83 |
01:58 ET | 2012 | 10.85 |
02:00 ET | 8613 | 10.85 |
02:02 ET | 10973 | 10.83 |
02:03 ET | 3625 | 10.83 |
02:05 ET | 10196 | 10.7836 |
02:07 ET | 1466 | 10.8 |
02:09 ET | 3570 | 10.785 |
02:12 ET | 10725 | 10.835 |
02:14 ET | 3631 | 10.83 |
02:16 ET | 700 | 10.83 |
02:18 ET | 4031 | 10.81 |
02:20 ET | 7865 | 10.8 |
02:21 ET | 5230 | 10.81 |
02:23 ET | 1512 | 10.85 |
02:25 ET | 3572 | 10.85 |
02:27 ET | 5447 | 10.835 |
02:30 ET | 3034 | 10.84 |
02:32 ET | 4869 | 10.8255 |
02:34 ET | 1316 | 10.825 |
02:36 ET | 1571 | 10.83 |
02:38 ET | 6325 | 10.85 |
02:39 ET | 5727 | 10.825 |
02:41 ET | 2200 | 10.825 |
02:43 ET | 11300 | 10.8 |
02:45 ET | 400 | 10.805 |
02:48 ET | 5214 | 10.79 |
02:50 ET | 2852 | 10.795 |
02:52 ET | 1140 | 10.82 |
02:54 ET | 4590 | 10.81 |
02:56 ET | 2366 | 10.82 |
02:57 ET | 10012 | 10.76 |
02:59 ET | 7231 | 10.77 |
03:01 ET | 24408 | 10.745 |
03:03 ET | 8815 | 10.755 |
03:06 ET | 15123 | 10.81 |
03:08 ET | 10282 | 10.84 |
03:10 ET | 10102 | 10.835 |
03:12 ET | 44887 | 10.8 |
03:14 ET | 4599 | 10.82 |
03:15 ET | 13501 | 10.845 |
03:17 ET | 48385 | 10.88 |
03:19 ET | 12967 | 10.93 |
03:21 ET | 6182 | 10.9364 |
03:24 ET | 274294 | 10.885 |
03:26 ET | 18804 | 10.925 |
03:28 ET | 13984 | 10.949 |
03:30 ET | 27735 | 10.9 |
03:32 ET | 11270 | 10.885 |
03:33 ET | 9401 | 10.88 |
03:35 ET | 310612 | 10.825 |
03:37 ET | 16826 | 10.85 |
03:39 ET | 30429 | 10.78 |
03:42 ET | 28760 | 10.785 |
03:44 ET | 7425 | 10.78 |
03:46 ET | 13121 | 10.79 |
03:48 ET | 18259 | 10.845 |
03:50 ET | 14775 | 10.845 |
03:51 ET | 16996 | 10.845 |
03:53 ET | 48064 | 10.84 |
03:55 ET | 72671 | 10.785 |
03:57 ET | 52927 | 10.785 |
04:00 ET | 627335 | 10.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kura Oncology Inc | 839.8M | -4.6x | --- |
Rapport Therapeutics Inc | 844.6M | 0.0x | --- |
Tyra Biosciences Inc | 801.0M | -9.9x | --- |
Bicara Therapeutics Inc | 885.8M | -16.0x | --- |
Autolus Therapeutics PLC | 782.3M | -2.4x | --- |
Anavex Life Sciences Corp | 772.5M | -18.2x | --- |
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $839.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 77.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.77 |
EPS | $-2.36 |
Book Value | $5.34 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.